Study to Evaluate the Efficacy and Safety of 0.1% and 0.03% Tacrolimus Ointment Administered in Adults With Moderate to Severe Atopic Dermatitis

Inclusion Criteria: * Patient may be male or female of any ethnic group * Patient without restricted legal competence, and suffers from moderate to severe atopic dermatitis (Rajka/Langeland score of at least 4.5) * Patient known to be responsive to topical steroids * Patient is capable of understanding the purposes and risks of the trial and has given written Informed Consent * Female patients of childbearing potential must agree to maintain adequate birth control practice during the trial period and during the first four weeks after the end of the study * Patient meets the following criteria: * Topical corticosteroids * Systemic corticosteroids (for the treatment of AD only) * Systemic non-steroidal immunosuppressants (e.g. cyclosporine, methotrexate) * Other investigational drugs * Light Treatments (UVA, UVB) * Patient has not taken and agrees not to take for the complete study period any medication or therapy prohibited by the protocol Exclusion Criteria: * Patient has a genetic epidermal barrier defect such as Netherton's syndrome or generalised erythroderma * Patient is pregnant or breast-feeding * Patient has a skin infection on the affected (and to be treated) area * Patient has a known hypersensitivity to macrolides in general, to tacrolimus or any excipient of the ointment * Patient is simultaneously participating in any other drug trial or less than 28 days have passed between the end of the previous trial and this one * Any form of substance abuse (including drug or alcohol abuse),psychiatric disorder or condition which, in the opinion of the investigator, may invalidate the communication with the investigator * Patient is known to be HIV positive